Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$3.38 USD
+0.17 (5.30%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.40 +0.02 (0.59%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VYGR 3.38 +0.17(5.30%)
Will VYGR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYGR
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Other News for VYGR
Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing ...
Voyager Therapeutics (VYGR) Enhances Alzheimer's Program with New Initiative | VYGR Stock News
Voyager Therapeutics continues expansion of its AD franchise
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | VYGR ...
Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)